HFR Wealth Management LLC Raises Holdings in Becton, Dickinson and Company (NYSE:BDX)

HFR Wealth Management LLC increased its holdings in Becton, Dickinson and Company (NYSE:BDXFree Report) by 1.9% in the 4th quarter, according to its most recent filing with the SEC. The institutional investor owned 31,359 shares of the medical instruments supplier’s stock after buying an additional 596 shares during the quarter. HFR Wealth Management LLC’s holdings in Becton, Dickinson and Company were worth $7,646,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in the stock. DiNuzzo Private Wealth Inc. bought a new position in shares of Becton, Dickinson and Company during the 4th quarter valued at $30,000. Fortitude Family Office LLC bought a new position in Becton, Dickinson and Company in the fourth quarter worth approximately $35,000. Venturi Wealth Management LLC boosted its stake in shares of Becton, Dickinson and Company by 552.0% during the 4th quarter. Venturi Wealth Management LLC now owns 163 shares of the medical instruments supplier’s stock worth $40,000 after acquiring an additional 138 shares during the last quarter. Arlington Trust Co LLC bought a new stake in Becton, Dickinson and Company during the fourth quarter valued at about $41,000. Finally, MCF Advisors LLC lifted its position in shares of Becton, Dickinson and Company by 51.4% during the 4th quarter. MCF Advisors LLC now owns 212 shares of the medical instruments supplier’s stock valued at $52,000 after buying an additional 72 shares in the last quarter. Hedge funds and other institutional investors own 86.97% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on the stock. Barclays increased their target price on shares of Becton, Dickinson and Company from $305.00 to $312.00 and gave the stock an “overweight” rating in a report on Monday, May 6th. The Goldman Sachs Group assumed coverage on shares of Becton, Dickinson and Company in a report on Thursday, May 30th. They issued a “buy” rating and a $274.00 target price for the company. Two research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $280.17.

View Our Latest Stock Report on Becton, Dickinson and Company

Insider Activity

In other news, SVP Thomas J. Spoerel sold 282 shares of the stock in a transaction that occurred on Thursday, March 14th. The stock was sold at an average price of $238.29, for a total transaction of $67,197.78. Following the completion of the transaction, the senior vice president now directly owns 2,276 shares in the company, valued at approximately $542,348.04. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other news, EVP Roland Goette sold 3,300 shares of the stock in a transaction that occurred on Wednesday, May 15th. The stock was sold at an average price of $236.73, for a total transaction of $781,209.00. Following the completion of the transaction, the executive vice president now directly owns 11,308 shares in the company, valued at approximately $2,676,942.84. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, SVP Thomas J. Spoerel sold 282 shares of the firm’s stock in a transaction on Thursday, March 14th. The stock was sold at an average price of $238.29, for a total value of $67,197.78. Following the completion of the sale, the senior vice president now owns 2,276 shares of the company’s stock, valued at $542,348.04. The disclosure for this sale can be found here. In the last ninety days, insiders sold 8,597 shares of company stock worth $2,028,786. 0.31% of the stock is currently owned by insiders.

Becton, Dickinson and Company Price Performance

BDX traded down $0.41 during trading on Tuesday, reaching $238.43. 491,245 shares of the company traded hands, compared to its average volume of 1,454,711. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.97 and a current ratio of 1.41. Becton, Dickinson and Company has a 12-month low of $224.00 and a 12-month high of $287.32. The firm has a fifty day simple moving average of $236.32 and a 200 day simple moving average of $237.90. The company has a market cap of $68.91 billion, a P/E ratio of 52.62, a PEG ratio of 2.03 and a beta of 0.44.

Becton, Dickinson and Company (NYSE:BDXGet Free Report) last announced its quarterly earnings data on Thursday, May 2nd. The medical instruments supplier reported $3.17 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.97 by $0.20. Becton, Dickinson and Company had a net margin of 6.76% and a return on equity of 13.90%. The business had revenue of $5.05 billion during the quarter, compared to analyst estimates of $5.04 billion. During the same period last year, the firm posted $2.86 EPS. The company’s revenue was up 4.6% on a year-over-year basis. On average, equities analysts forecast that Becton, Dickinson and Company will post 13.03 EPS for the current year.

Becton, Dickinson and Company Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, June 28th. Stockholders of record on Monday, June 10th will be given a dividend of $0.95 per share. The ex-dividend date is Monday, June 10th. This represents a $3.80 dividend on an annualized basis and a dividend yield of 1.59%. Becton, Dickinson and Company’s dividend payout ratio is currently 83.70%.

Becton, Dickinson and Company Company Profile

(Free Report)

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.

Featured Stories

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDXFree Report).

Institutional Ownership by Quarter for Becton, Dickinson and Company (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with MarketBeat.com's FREE daily email newsletter.